Chronic spontaneous urticaria (CSU) is a prevalent, potentially debilitating disease that can prove challenging to manage successfully. Although antihistamines, anti-IgE monoclonal antibodies, and off-label suppressants can alleviate recurrent hives and angioedema, many patients with CSU are refractory to treatments comprising the standard of care. These limitations have spurred the development and examination of novel agents, such as BTK inhibitors, in patients with inadequately controlled disease. Through this three-part, small-group educational program, allergists, dermatologists, and other ancillary clinicians can learn how to more effectively navigate the CSU differential diagnosis, select the most appropriate therapies, and address more challenging management scenarios tied to treatment de-escalation. In doing so, healthcare providers can ensure that the rash of therapeutic developments in CSU are used to their fullest potential.

CME/CE Accreditation Information